23rd International Reid Bioanalytical Forum (REID)

Outline Programme
The main Forum will run from the evening of Monday 23^rd September to midday on Thursday 26^th September, 2019. Already secured in an ever developing program, Prof. Perdita Barran (Manchester University) will deliver a keynote talk on “Bioanalysis of the Future”, Roland Staack (Roche) speak on the subject of “Free/Active/Total Drug Quantification by LBA, LC-MS”, alongside a presentation by the ever insightful Philip Timmerman (EBF).

Register for the event here

Submit an abstract for consideration here

Sponsorship for the event here

 

View the BioForum 2019 circular here

To view ‘A note from Tim Sangster – the 23rd International Reid Bioanalytical Forum’ click here

 

• “Bioanalysis of the Future” – Including gene & cell therapies, novel delivery systems, high resolution MS and alternative sample collection techniques

•  “Regulatory Aspects” – With a presentation from the European Bioanalytical Forum and a talk on hot topics from the MHRA inspection team, amongst others

• “Open Session” – On the theme of challenges, solutions and outcomes relevant to bioanalytical science

•  “Ask the Doctor” – Interesting and unusual case studies with novel outcomes

•  “Impact of Bioanalytical Science” – A focus on delivering better solutions in the clinic, including the latest micro-sampling techniques

•  “What are the requirements of the next generation of Bioanalytical Scientists?” A note from the session lead, Jaap Wieling (BiosanaPharma, The Netherlands):
  In the early decades of modern bioanalysis (80’s, 90’s), rapidly evolving bioanalytical technologies enabled pharmacologists to gain vast in-vivo knowledge on their compounds and required pharma companies to maintain substantial and very skilled bioanalytical capabilities. In the decades that followed (00’s, 10’s) the pace of technology development slowed down and enabled pharma companies to reduce their in-house bioanalytical capabilities and (partly) outsource these activities to CRO’s. The focus for pharma bioanalytical groups became building knowledge of the compounds rather than technologies, whilst CRO’s built their capacity and bioanalytical skills.The current situation is that CRO’s now have large capacity and similar high-level technology skillsets to that of their customers, applied to a wide variety of compound classes. They have become a valuable source for pharma companies to acquire technological and scientific expertise and knowledge for new modalities.This looks like an ideal combination of the bioanalytical CRO offering capacity, technology and skills with the pharma company needing to rapidly acquire additional knowledge on their compound by tapping in to this expertise and use CRO’s prior knowledge with the challenges without trespassing on IP barriers.

This combination requires pharma company bioanalysts to adopt skills to optimally benefit from CRO’s (communication, planning) and CRO’s to understand pharma’s needs other than just capacity, revenue maximization and a good price (communication, drug development etc.). This session is set up to discuss the requirements of the next generation bioanalytical scientists in academia, CRO’s and pharma. How are people developed and how can they be trained to optimally serve drug development, regardless of where they work?

Biomarkers Training Course – Dr Radboud van Trigt, Director of Bioanalytical Science of PRA Health Sciences, and colleagues (include lunch)

This training, in the Monday afternoon 12.00-17.00 prior to the full Reid conference, will offer attendees an introduction to the interesting and challenging world of bioanalysis for biomarkers. The role of a biomarker typically changes over time and can develop from an exploratory assessment to a primary end-point for a clinical study. This has consequences for the method, its validation and regulatory expectations. The course will cover the importance of biomarker analysis and regulatory aspects for biomarkers in drug development. It will also contain several technology-based sessions providing information on different platforms used for biomarker analysis. This will include clinical chemistry platforms, ligand-binding assays, LC-MS/MS, flow cytometry, genomics and other platforms. Special attention will be given to the differences between biomarker and PK assays and on ways to monitor and improve quality of biomarker data in order to provide the end-users the information they need.